Medpace Holdings Inc vs Vanguard High Dividend Yield ETF — how do they compare? Medpace Holdings Inc trades at $598 (market cap $16.90B), while Vanguard High Dividend Yield ETF trades at $166.89. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | VYM | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | — |
52-Week High | $620.59 | $166.67 |
52-Week Low | $393.42 | $136.99 |
Enterprise Value | $16.52B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
VYM trades at $166.67, up 0.37% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF is highlighted in recent news for retirement income strategies, with a dividend of $0.98 scheduled for June 2026. It has shown strong performance, reaching new highs, though some articles note long-term underperformance versus the S&P 500.
The outlook is positive for income-focused investors due to its high-dividend yield and diversification, but risks include potential yield compression and market volatility. Analyst sentiment is mixed, with some advocating for its value exposure while others caution on growth limitations.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →